Metrics as of 10/17/2026, 08:43 AM (Berlin time), refresh in progress.
Aktis Oncology Stock
Aktis Oncology, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Matthew Roden
- Employees
- 79
- Market cap
- $809 M
- IPO
- 09/01/2026
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed…
Aktis Oncology stock: price history
1D
-5.9%
1W
-17.0%
1M
-33.7%
6M
-25.6%
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~18% stronger price swings than usual
Ask the agents about Aktis Oncology
Analyst assessment of Aktis Oncology
PRICE TARGET LOW
US$35.00
CONSENSUS
US$37.40
MEDIAN
US$37.00
PRICE TARGET HIGH
US$40.00
0
STRONG BUY
6
BUY
3
HOLD
0
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 02/10/2026
Aktis Oncology stock metrics
P/E
-14.34
P/B
1.72
EV/EBITDA
-9.5
RETURN ON EQUITY
-5.0%
NET MARGIN
-713.5%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
0.9%
FLOAT SHARES
486,229
AVG. DAILY VOLUME (30D)
469,013
Insider transactions (SEC)
Czibere Akos
Czibere Akos
Czibere Akos
Herrmann Ken
Herrmann Ken
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -5.9%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Aktis Oncology stock
What does Aktis Oncology do?
Aktis Oncology, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Matthew Roden, the company employs around 79 people.
The IPO was on 09/01/2026; the stock trades on NASDAQ under the ticker AKTS.
What do analysts say about Aktis Oncology stock?
9 analysts rate the stock, the consensus is Buy (as of 02/10/2026).
The average price target is US$37.40, ranging from US$35.00 to US$40.00, with a median of US$37.00.
This is an external assessment, not a statement by Market Jury.
When does Aktis Oncology report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 18% stronger than usual.
Does Aktis Oncology pay a dividend?
No, Aktis Oncology currently does not pay a dividend.
Which stocks are comparable to Aktis Oncology?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Aktis Oncology stock analyzed?
Clicking "Analyze stock" lets five strategies assess Aktis Oncology against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.